Ref ID: 2746
Author:
J. STONE1, S. HOLLAND1, P. WICKERSHAM1, P. DEUTSCH1, G. WINCHELL1, M. HESNEY1, R. MILLER1, A. FREEMAN1, S. DILZER2, K. LASSETER2
Author address:
1Merck Research Laboratories, West Point, PA, 2Clinical Pharmacology Associates, Miami, FL.
Full conference title:
ICAAC 41st
Abstract:
Background: Caspofungin (CancidasTM, MK-0991, L-743,872) is a parenteral antifungal agent that inhibits the synthesis of 1,3 b-D glucan, an essential component of the fungal cell wall.
Methods: The potential for drug interactions between caspofungin and tacrolimus (FK-506) was evaluated in a placebo-controlled, randomized, Phase I study. Part (1) was a 2-period, parallel-panel study in which healthy subjects received tacrolimus (2 doses of 0.1 mg/kg oral capsules administered 12 hours apart, n=12) or placebo (n=5) alone in Period 1 and again on Day 10 of caspofungin 70 mg IV daily in Period 2. In Part (2), parallel panels of healthy subjects received tacrolimus (2 doses of 0.1 mg/kg 12 hours apart, n=8) or placebo (n=8) on Days 1 and 10 of caspofungin 50 mg IV daily.
Results: The geometric mean ratio (90% CI) for caspofungin plasma AUC(0-24hr) under coadministration relative to administration alone was 1.00 (0.96, 1.04) for Part (1) and 1.05 (0.96, 1.15) for Part (2), based on a mixed-model analysis that evaluated pharmacokinetic data obtained on Days 9 and 10 in both the coadministration and the placebo-control panels. The geometric mean ratio (90% CI) for tacrolimus whole blood AUC(0-12hr) in Period 2 (coadministration) relative to Period 1 (administration alone) was 0.80 (0.72, 0.89) for Part (1), based on a combined analysis of morning and evening doses. Reductions of similar magnitude were also seen for tacrolimus CMAX and C12hr. Conclusions: Tacrolimus does not alter the pharmacokinetics of caspofungin. Caspofungin modestly reduces whole blood concentrations of tacrolimus. For patients receiving both therapies, standard monitoring of tacrolimus blood concentrations and appropriate tacrolimus dosage adjustments are recommended.
Abstract Number: NULL
Conference Year: 2001
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Srisombat Puttikamonkul1, Sven D.
Willger1, Nora Grahl1, John R. Perfect2, Navid Movahed3, Brian Bothner3, and Robert A2011
NULL
n/a
-
v
Ken Oda, Mara Couto-Rodriguez, Susan Cowden, John Kerry,
Michelle Momany,2011
31)
n/a
-
v
Praveen R Juvvadi, Jarrod R Fortwendel, Luise E Rogg, and William J Steinbach.
2011
NULL
n/a
-
v
Mara Couto-Rodríguez, Susan Cowden, Ken Oda and Michelle Momany.
2011
29)
n/a
-
v
Mizuki Tanaka, Takahiro Shintani, and Katsuya Gomi
2011
28)
n/a
-
v
Sara J.Blosser, Sven D.Willger, Robert A. Cramer Jr
2011
27)
n/a
-
v
Hironobu Ogasawara , Saori
Takahashi , and Katsuya Gomi2011
26)
n/a
-
v
Özlem Sarikaya Bayram ,
Özgür Bayram , Oliver Valerius , Hee Soo Park , Stefan Irniger , Jennifer Gerke , Min Ni , Kap-Hoon Han , Jae-Hyuk Yu and Gerhard H. Braus2011
25)
n/a
-
v
Kap-Hoon Han1, Seul-A Gu, Jae Sin Park, Lee Han Kim, Dong-Soon Oh1, and Dong Min Han
2011
24)
n/a
-
v
Maria Macios , Piotr Wëgleñski , Agnieszka Dzikowska
2011
23)
n/a